This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AVAH vs. ELAN: Which Stock Is the Better Value Option?
by Zacks Equity Research
AVAH vs. ELAN: Which Stock Is the Better Value Option?
Elanco Animal Health Incorporated (ELAN) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 7.69% and 3.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Elanco (ELAN) Ahead of Earnings?
by Zacks Equity Research
Elanco (ELAN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Elanco Animal Health Incorporated (ELAN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Elanco Animal Health Incorporated (ELAN) Could Beat Earnings Estimates Again
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Zacks Analyst Blog Highlights: National Vision, DaVita, Elanco Animal Health, Henry Schein and Phibro Animal Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: National Vision, DaVita, Elanco Animal Health, Henry Schein and Phibro Animal Health
5 Probable MedTech Winners Post-COVID on Discounted PEG
by Zacks Equity Research
Here are some MedTech stocks with favorable PEG ratio, which are expected to provide gains in 2021.
Top Ranked Momentum Stocks to Buy for June 9th
by Zacks Equity Research
TITN, NVDA, GIII, and ELAN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 9, 2021.
Top Ranked Momentum Stocks to Buy for May 21st
by Zacks Equity Research
ARCB, CNR, ELAN, and OSK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 21, 2021
What's in Store for Intersect ENT's (XENT) Q1 Earnings?
by Zacks Equity Research
PROPEL and SINUVA are expected to have contributed to Intersect ENT's (XENT) first-quarter revenues.
Elanco Animal Health Incorporated (ELAN) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 60.87% and 7.36%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Elanco (ELAN)
by Zacks Equity Research
Elanco (ELAN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Healthcare Stock Q1 Earnings Due on May 7: ELAN, MD, MODV
by Sapna Bagaria
Varied companies across the vast healthcare space might have been affected differently by the COVID crisis during the first quarter.
Elanco Animal Health Incorporated (ELAN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why the Earnings Surprise Streak Could Continue for Elanco Animal Health Incorporated (ELAN)
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Thermo Fisher (TMO) to Report Q1 Earnings: WIll It Beat?
by Zacks Equity Research
Fewer hospital visits on growing new cases might have once again impacted the level of routine diagnostics testing activity for Thermo Fisher (TMO) in Q1.
New Launches in Breast Health to Aid Hologic (HOLX) Q2 Earnings
by Zacks Equity Research
Strength in Molecular Diagnostics business is likely to have continued to aid Hologic's (HOLX) performance in the second quarter of fiscal 2021.
BioRad (BIO) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Growing demand for Polymerase Chain Reaction and Droplet Digital PCR products is expected to have contributed to BioRad's (BIO) Q1 growth.
ResMed (RMD) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Improvement in demand for Mask and Other accessories along with rapid adoption of digital health solution is likely to have contributed to ResMed's (RMD) Q3 growth.
LabCorp (LH) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
With respect to LabCorp's (LH) COVID-19 testing services wing, although extensive vaccine rollouts are ongoing, the resurgence of the virus might have once again boosted testing demand in Q1.
Boston Scientific's (BSX) Watchman US Sale to Aid Q1 Earnings
by Zacks Equity Research
Within Boston Scientific's (BSX) coronary therapies, drug-eluting stents sale continue to be a challenge from a pricing standpoint in Q1.
Integra (IART) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
The acquisition of ACell, and faster recovery growth rate in Japan and China are likely to have helped recover Integra's first-quarter 2021 performance.
VITUS to Hurt Chemed (CHE) Q1 Earnings, Roto-Rooter to Aid
by Zacks Equity Research
The federal government's recent approach in terms of relaxing regulations, allowing broader use of telehealth, is likely to have helped in some sort of recovery of Chemed's (CHE) VITAS business in Q1.
Amedisys (AMED) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Growth in Home Health and Hospice along with recent innovation and acquisitions is expected to have contributed to Amedisys (AMED) top-line growth in Q1.
Molecular Tests to Drive Quest Diagnostics (DGX) Q1 Earnings
by Zacks Equity Research
Through the first quarter, Quest Diagnostics' (DGX) several significant strides in the field of COVID-19 diagnostic testing are expected to have contributed to the top line.